Ticker

Cumberland Pharmaceuticals Inc. has transformed from a commercial-stage pharma to a pre-revenue, Phase 2-stage biotech focused on rare diseases. Recent $100M asset sale to Apotex funds operations and pipeline, with a special dividend paid to shareholders and four late-stage clinical programs retained. All pipeline assets are based on ifetroban, targeting high-value indications like DMD cardiomyopathy, cancer…

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX - Get Free Report) passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $4.87 and traded as high as $8.15. Cumberland Pharmaceuticals shares last traded at $7.96, with a volume of 79,334 shares traded. Analysts Set New Price Targets CPIX has

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript

Cumberland Pharmaceuticals NASDAQ: CPIX reported a second-quarter operating loss of $3.1 million as it prepared to transition from a commercial-stage specialty pharmaceutical company into an innovation-focused biopharmaceutical business following the sale of its branded U.S. commercial portfolio to Apotex Health.

$100 million Strategic Transaction Closed Special Shareholder Dividend Funded Advancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company, announced today its second quarter 2026 financial results and provided an update following the successful closing of its Strategic Transaction with Apotex…